Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norepinephrine + phenylephrine is a combination of two sympathomimetic vasopressors used primarily in critical care settings to manage hypotension, especially in cases such as septic shock. Norepinephrine acts as an agonist at both alpha-1 and beta-1 adrenergic receptors, leading to vasoconstriction and increased cardiac output. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that causes vasoconstriction with minimal direct effect on the heart. The combination aims to increase systemic vascular resistance and maintain adequate blood pressure during severe hypotensive states. However, clinical studies suggest that this combination may be associated with higher mortality compared to norepinephrine alone in patients with septic shock[1]. Both agents are administered intravenously in acute care settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norepinephrine + phenylephrine.